Sacubitril/valsartan is a first-in-class ARNI that combines neprilysin inhibition with AT1 receptor blockade. The PARADIGM-HF trial demonstrated a 20% reduction in cardiovascular death and heart failure hospitalization compared to enalapril, establishing it as a cornerstone of HFrEF therapy. It has largely replaced ACE inhibitors as the preferred RAAS inhibitor in HFrEF.
Superior to enalapril in reducing CV death and HF hospitalization (PARADIGM-HF)6
20% reduction in cardiovascular death vs enalapril1,3
Reduces cardiac remodeling
Improves symptoms and quality of life in heart failure2,5
What to watch for
Hypotension (most common reason for dose reduction)
Hyperkalemia
Cough (less than ACE inhibitors)
Concurrent ACE inhibitor use (36-hour washout period required)2
History of angioedema with ACE inhibitors or ARBs
The bottom line
Evidence rating strong. Most-documented uses: superior to enalapril in reducing cv death and hf hospitalization (paradigm-hf), 20% reduction in cardiovascular death vs enalapril, reduces cardiac remodeling. 10 sources indexed (2020–2023), with 2 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
Combines two mechanisms: sacubitril (a prodrug) is converted to sacubitrilat, which inhibits neprilysin, an enzyme that degrades natriuretic peptides (ANP, BNP, CNP), bradykinin, and adrenomedullin. This enhances these beneficial peptides' vasodilatory, natriuretic, and anti-fibrotic effects. Valsartan blocks the AT1 receptor, preventing the deleterious effects of angiotensin II. The combination provides both neurohormonal suppression and enhancement of protective pathways.1,2
Class
Angiotensin Receptor-Neprilysin Inhibitor (ARNI)
Dosing
Dosing & protocol.
Common range
Starting: 24/26 mg or 49/51 mg twice daily; Target: 97/103 mg twice daily (as prescribed by your physician)
Recommended form
Oral tablet
Can be taken with or without food; 36-hour washout required when switching from an ACE inhibitor to prevent angioedema
Depletions
What it depletes.
Nutrients this medication can lower over time, and what to replace.
Zinc
Mild
ARB therapy can modestly increase urinary zinc losses in some users, though typically less than ACE inhibitors.
Sacubitril/valsartan combines neprilysin inhibition with angiotensin receptor blockade and meaningfully raises serum potassium by suppressing aldosterone. In the PARADIGM-HF heart-failure trial, hyperkalemia greater than 5.4 mmol/L occurred in roughly 20% of treated patients. Adding a potassium supplement on top of this layered RAAS blockade can push potassium into dangerous territory, particularly in patients with chronic kidney disease or those also on spironolactone, eplerenone, or NSAIDs.
Recommendation: Do not take potassium supplements with sacubitril/valsartan unless your cardiologist has confirmed a true deficiency. If both are needed, get potassium checked within 1-2 weeks of starting and after every dose change. Avoid potassium-containing salt substitutes.
The valsartan component blocks AT1 receptors, reduces sodium reabsorption, and increases lithium retention by the kidney. A published case described an 81-year-old on chronic lithium developing progressive tremor, ataxia, and cognitive decline after starting sacubitril/valsartan. Lithium Orotate doses are smaller but use the same renal pathway, and the therapeutic window is narrow.
Recommendation: Avoid Lithium Orotate while taking sacubitril/valsartan. If you must combine them, keep the dose low, stay well hydrated, and ask your cardiologist to check serum lithium after 1-2 weeks. Hold the supplement during vomiting, diarrhea, or fever.
Zheng S, Zhang Y, Gu L et al.. Renal Safety of Sacubitril/Valsartan: A Meta-Analysis of Randomized Controlled Trials. Journal of cardiovascular pharmacology. 2023
Chen Y, He Q, Mo DC et al.. The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials. Medicine. 2022
Huang Y, Zhang Y, Ma L et al.. Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials. Journal of cardiovascular pharmacology. 2021
Martins E Pereira G, S Duarte G, Katerenchuk V et al.. Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis. Expert opinion on drug safety. 2021
Chen X, Jin C, Xie L et al.. LCZ696 and preservation of renal function in heart failure: A meta-analysis of 6 randomized trials. Reviews in cardiovascular medicine. 2020
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Sacubitril/Valsartan in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack